This grant proposal represents the University of California, Davis' request for funded participation in the Southwest Oncology Group (SWOG). Under the auspices of this grant, two major institutions, the University Medical Center in Sacramento (UCDMC) and the Veteran's Administration Medical Center in Martinez (MVAMC), in collaboration with private practice physicians throughout the northern central valley, will coordinate clinical trials activities in an eight county area serving a population of greater than two million. UC Davis was a very active participant in the Northern California Oncology Group. It is our goal to continue this participation with our recent acceptance into the Southwest Oncology Group. Our clinical trials network remains in place. We anticipate a combined institutional accrual of 150 patients per year on NCI approved protocols. Our activities will be enhanced by a new 40,000 sq. ft. Cancer Treatment Facility that will include a Radiation Oncology Center, scheduled to open at UCDMC in early 1988. We have already begun to provide clinical expertise to SWOG in the areas of GU oncology, lung cancer and hematologic oncology. This clinical expertise is supported by laboratory-based investigations. We are participants in the Bladder Cancer Flow Cytometry network (R01 funded). Dr. Ralph deVere White has been named Chair of the SWOG GU Subcommittee on Flow Cytometry. Dr. Jerry Lewis is a member of the SWOG Leukemia Subcommittee on Cytogenetics. We have proposed three trials for SWOG consideration. Therapeutic approaches to cancer initiated at UC Davis include monoclonal antibody imaging and therapy trials; high dose platinum (day 1 & 8) in lung cancer; and carboplatinum in relapsed ANLL. Our SWOG membership will be one important effort to ensure the widespread dissemination of state-of-the-art cancer care and cancer control throughout the northern central valley of California.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA046441-04
Application #
3558759
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1988-01-01
Project End
1992-12-31
Budget Start
1991-01-01
Budget End
1991-12-31
Support Year
4
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
Schools of Medicine
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2016) Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer 17:113-8.e1-2
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Advani, Ranjana H; Hong, Fangxin; Fisher, Richard I et al. (2015) Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol 33:1936-42
Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2015) Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol 10:110-5
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8

Showing the most recent 10 out of 129 publications